Adequacy of oophorectomy at the time of gynecologic surgery

Occult residual ovarian tissue at the time of minimally invasive risk reducing surgery in women with BRCA mutations

OBJECTIVE

To describe extension of ovarian tissue beyond visible and National Comprehensive Cancer Network recommended margins among patients with BRCA mutations undergoing minimally invasive risk-reducing salpingo-oophorectomy.

METHODS

A prospective study of patients with BRCA mutations who underwent minimally invasive risk-reducing bilateral salpingo-oophorectomy was conducted. Patient enrollment occurred between October 2021 and 2023. Tissue specimens were analyzed according to the Sectioning and Extensively Examining the Fimbriated End protocol.

RESULTS

Twenty women with BRCA mutations were prospectively enrolled. All patients underwent minimally invasive surgery with 70% undergoing concurrent hysterectomy (n = 14). Approximately half of these procedures were performed with robotic assistance (n = 9, 45%). One patient was admitted overnight (5%); the other nineteen were discharged on the day of surgery (95%). One patient experienced a major complication and required readmission (5%). Extension of ovarian tissue beyond the visible ovary was noted on pathologic examination of six specimens (30%). In one patient this was observed on the left (17%), in three on the right (50%), and in two bilateral extension (33%) was noted. The distance ovarian stroma extended microscopically beyond the visible ovary was between 2 and 14 mm, with a median of 5 mm. Among patients with microscopic extension of ovarian tissue, the majority (n = 5, 83%) had a BRCA2 mutation.

CONCLUSION

In women with BRCA mutations undergoing risk-reducing minimally invasive surgery, approximately one third had microscopic extension of ovarian stroma beyond the visible ovary. Current guidelines which recommend resection of at least 20 mm of tissue beyond the visible ovary are likely adequate in this population.

Opportunistic salpingectomy during vaginal hysterectomy for a benign pathological condition

INTRODUCTION AND HYPOTHESIS

The objective was to evaluate the surgical feasibility of opportunistic salpingectomy or salpingo-oophorectomy during benign vaginal hysterectomy (HV) and the prevalence of occult tubal lesions.

METHODS

In this prospective study from 1 September 2013 to 1 November 2015, the prevalence of bilateral salpingectomy with or without ovariectomy and the prevalence of histopathological and immunohistochemical tubal abnormalities were assessed.

RESULTS

A total 115 patients were included. Bilateral salpingectomy was performed in 85 patients (73.92%; group A) and was technically impossible in 30 patients (26.08%; group B). Older patients (62.9 vs 57.5 years, p = 0.009), menopausal status (83.33% vs 62.35%, p = 0.03) and elevated BMI (27.58 vs 25.05 p = 0.03) were statistically associated with failure of salpingectomy. There was only one case of postoperative hemorrhage in group A. There was no difference with regard to intra- or postoperative complications, blood loss, and operating time between the two groups. Among the 67 fallopian tubes analyzed with a validated histopathological protocol, there were 8 (11.94%) immunohistochemical abnormalities with a "p53 signature."

CONCLUSIONS

With the recent demonstration of a tubal origin of most ovarian cancer, opportunistic salpingectomy could be a theoretically relevant prevention strategy. Bilateral salpingectomy could be performed during benign vaginal hysterectomy by experienced surgeons. The advantages and disadvantages of exclusive salpingectomy during pelvic floor surgery should be discussed with the patients.

Prophylactic adnexectomy along with vaginal hysterectomy for benign pathology

OBJECTIVE

This study was designed to evaluate the safety and feasibility of prophylactic adnexectomy during vaginal hysterectomy for benign pathology.

METHODS

We retrospectively reviewed medical records of all patients who underwent vaginal hysterectomy (VH) between 2008 and 2010. Clinical comparison of patients who underwent VH with adnexectomy (n = 92) and VH only (n = 686) was performed. Clinical characteristics (age, parity, body mass index, and previous pelvic surgery), surgical outcomes (uterine weight, operative time, estimated blood loss, pelvic adhesion, hemoglobin change and hospital stay) and intra- and postoperative complications (transfusion, bladder injury and fever) were evaluated.

RESULTS

Clinical characteristics except for age (45.44 years for VH only vs. 47.15 years for VH with adnexectomy, P = 0.007) were not different between the two groups. Similarly, surgical outcomes and complication rates were not different between the two groups.

CONCLUSION

Prophylactic bilateral adnexectomy can be performed safely during VH.

Removal of adnexa at the time of vaginal hysterectomy

Removal of the fallopian tubes and ovaries at the time of vaginal hysterectomy is a skill that must be acquired if one is to be a competent vaginal surgeon. Various techniques have been described and will be reviewed in this chapter. A single technique or series of steps often must be modified depending on the descent of the adnexa, size and shape of the pelvis, and intraperitoneal pathology. The pelvic surgeon must adhere to the basic surgical principles and understand the anatomic relationships of the adnexa to other pelvic viscera, including the lower urinary tract. Preoperative discussion with all patients regardless of age is imperative in determining their desires for oophorectomy at the time of vaginal hysterectomy.

[Retained ovarian remnant carcinoma: a case report]

Ovarian remnant syndrome is defined as residual ovarian tissue non intentionally left in place by the surgeon during a bilateral salpingo-oophorectomy. Patients present various symptoms usually including chronic pelvic pain, pelvic mass, bowel obstruction, hydronephrosis due to ureteral compression. We report a case of adenocarcinoma arising in such an ovarian remnant revealed by vaginal bleeding 5 years after total abdominal hysterectomy and bilateral oophorectomy for uterine fibroids. It was regarded as stage IIIc according to the FIGO classification because of common iliac lymph node involvement while there was no ascitis, no peritoneal nor omental implant but a unilateral hydronephrosis induced by extrinsec ureteral obstruction. Complete cytoreductive surgery was achieved including partial bladder and lower ureteral resection with colpectomy, omentectomy, pelvic and para-aortic lymphadenectomy. Paclitaxel-Platinum combination chemotherapy was given for nine cycles.